# Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO)

> **NCT01976338** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 283 (actual)

## Conditions studied

- Macular Edema Secondary to Branch Retinal Vein Occlusion

## Interventions

- **DRUG:** Ranibizumab 0.5 mg
- **OTHER:** Sham injection

## Key facts

- **NCT ID:** NCT01976338
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11-12
- **Primary completion:** 2016-03-28
- **Final completion:** 2016-03-28
- **Target enrollment:** 283 (ACTUAL)
- **Last updated:** 2017-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01976338

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01976338, "Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01976338. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*